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Abstract
Background: Upon Ag-activation cytotoxic T cells (CTLs) produce IFN-γ GM-CSF and TNF-α,
which deliver simultaneously pro-apoptotic and pro-inflammatory signals to the surrounding
microenvironment. Whether this secretion affects in an autocrine loop the CTLs themselves is
unknown.
Methods:  Here, we compared the transcriptional profile of Ag-activated, Flu-specific CTL
stimulated with the FLU M1:58-66 peptide to that of convivial CTLs expanded in vitro in the same
culture. PBMCs from 6 HLA-A*0201 expressing donors were expanded for 7 days in culture
following Flu M1:58-66 stimulation in the presence of 300 IU/ml of interleukin-2 and than sorted
by high speed sorting to high purity CD8+ expressing T cells gated according to FluM1:58-66
tetrameric human leukocyte antigen complexes expression.
Results: Ag-activated CTLs displayed higher levels of IFN-γ, GM-CSF (CSF2) and GM-CSF/IL-3/IL-
5 receptor common β- chain (CD131) but lacked completely expression of IFN-γ receptor-II and
IFN-stimulated genes (ISGs). This observation suggested that Ag-activated CTLs in preparation for
the release of IFN-γ and GM-CSF shield themselves from the potentially apoptotic effects of the
former entrusting their survival to GM-SCF. In vitro phenotyping confirmed the selective surface
expression of CD131 by Ag-activated CTLs and their increased proliferation upon exogenous
administration of GM-CSF.
Conclusion: The selective responsiveness of Ag-activated CTLs to GM-CSF may provide an
alternative explanation to the usefulness of this chemokine as an adjuvant for T cell aimed vaccines.
Moreover, the selective expression of CD131 by Ag-activated CTLs proposes CD131 as a novel
biomarker of Ag-dependent CTL activation.
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Background
In vivo animal models suggest that the activation of CD8-
expressing cytotoxic T cells (CTLs) follows a linear pattern
in which an expansion phase occurring within the first
week after Ag stimulation rapidly evolves into a contrac-
tion phase in which surviving memory CTLs resume a qui-
escent phenotype [1,2]. During the expansion phase, Ag-
activated CTLs boast a robust enhancement of effector
functions including the activation of cytotoxic mecha-
nisms and the production of pro-inflammatory cytokines
such as interferon (IFN)-γ. It is believed that such activa-
tion occurs through signaling associated with the Ag-spe-
cific triggering of the T cell receptor (TCR) combined with
other co-stimulatory signals. In summary, naïve and, to a
certain degree, long-term memory CTL activation and
expansion is dependent upon three types of stimulation
[3]; the first is the direct interaction between the TCR and
the major histocompatiblity (MHC)/epitope complex.
This interaction determines the specificity of the activa-
tion. However, TCR triggering is not sufficient by itself to
sustain a forceful activation and expansion of CTLs and it
may lead to unresponsiveness if others stimulatory signals
are not provided simultaneously. A second signaling
requirement is absolved by cell-to-cell interactions involv-
ing co-stimulatory molecules expressed on the surface of
Ag-presenting cells. This interaction may sustain a few cell
divisions but is insufficient to induce clonal expansion
and full activation of effector functions. Thus, a third sig-
nal is needed, which is provided by immune-modulatory
cytokines released by Ag-presenting cells, helper T cells or
other immune cells in response to pro-inflammatory sig-
nals provided by pathogens or other environmental con-
ditions. This third signal can be modeled experimentally
by the exogenous administration of pro-inflammatory
cytokines such as interleukin (IL)-2 [4].
Recombinant human IL-2 has been extensively used for
the selective in vitro expansion of CTLs naturally exposed
in vivo to Ag such as tumor infiltrating lymphocytes [5] or
vaccine-induced circulating lymphocytes [6]. The in vitro
expansion of CTLs exposed to Ag in vivo, strictly requires
cytokine stimulation (as exemplified by IL-2); further-
more, in vitro stimulation in the presence of IL-2 leads not
only to selective expansion of Ag-specific CTLs but also to
the activation of their effector functions [4] paralleling the
expansion phase described in other experimental models
[1,7].
Segregating the respective contribution of Ag-specific sig-
naling and environmental co-stimulation within the same
microenvironment may provide useful insights about the
mechanisms involved in the selective activation of Ag-
exposed CTLs within a T cell population and shed light on
the requirements for full activation of CTL effector func-
tions in the target organ during distinct immune reactions
including tumor regression following immunotherapy
[8,9], acute allograft rejection [10], clearance of viral
infection [11] and flares of autoimmunity [12].
In a simplified in vitro model of human CTL activation, we
previously observed that neither Ag-stimulation in the
presence of signal two nor the presence of signal 3 alone
could induce in vitro expansion and activation of Ag-
exposed CTLs and only the combination of the three
could induce effective CTL responses [4]. Analysis of the
transcriptional patterns associated with the complete acti-
vation of effector CTL responses suggested that prolifera-
tion and effector function were both dependent upon the
combined presence of the three signals. However, further
dissection of transcriptional patterns induced by the
administration of IL-2 to peripheral blood mononuclear
cells (PBMC) or non Ag-activated CD4 and CD8 T cell
sub-populations suggested that the effects of IL-2 on T cell
signaling are powerful but non-specific in the absence of
TCR triggering [13]. Thus, to discriminate the individual
contribution of direct TCR triggering on CTL activation,
we compared the transcriptional profile of Ag-exposed
CTLs to non-Ag-exposed, non-proliferating CTLs sharing
identical environmental conditions. The model evaluated
the kinetics of proliferation of HLA-A*0201-restricted, Flu
Matrix protein epitope M1:58-66-specific CTLs; seven
days following in vitro Ag stimulation with M1:58-66 and
in vitro culture in 300 IU of human recombinant IL-2
(Novartis-Chiron CO, Emeryville CA), we separated with
tetrameric flu-specific human leukocyte antigen/com-
plexes (tHLA) proliferating CTLs from their companions
CD8 expressing T cells (convivial CTLs).
Materials and methods
Transcriptional characteristics of stimulated versus resting 
CD8 expressing T cells
In vitro sensitization (IVS)
PBMCs were obtained by leukapheresis from HLA-
A*0201-expressing normal volunteers and frozen after
Ficoll separation. HLA-A*0201 expression was docu-
mented by sequence-based typing [14]. PBMCs from 6
donors were thawed and plated in complete Iscove
medium (Life Technologies, Grand Island, NY) supple-
mented with 10% heat inactivated human AB serum, 10
mM HEPES buffer, 100 U/ml penicillin-streptomycin, 0.5
mg/ml amphotericin B and 0.03% glutamine, at the den-
sity of 106 cells/well in 48 multiwell plate. After overnight
panning, cells were pulsed at day 1 with 1 μM Flu M1:58-
66 peptide (Princeton Biomolecules, Langhorne, PA) and
the following day human recombinant IL-2 300 IU/ml
(rHuIL-2, Chiron Co, Emeryville, CA) was added. IL-2 was
added every two days. At day 1, T cells were stained with
Carboxy Fluoroscein Succinimidyl Ester (CFSE) to moni-
tor their proliferation. PBMC cultures were continued for
7 days till sorting.Journal of Translational Medicine 2008, 6:17 http://www.translational-medicine.com/content/6/1/17
Page 3 of 10
(page number not for citation purposes)
Cell sorting
On the eight day in culture, CD8-expressing T cells were
enriched by negative selections using magnetic beads
before sorting (Miltenyi Biotec, Auburn, CA) on an
autoMACS separator. Median purity of CD8 T cells eluted
from the columns was 85%. Sorting was then performed
by high speed flow-cytometry (FACSVantage SE, BD); a
logical gate was applied on SSC and live/dead staining
with DAPI to check the viability of sorted cells. The sorting
was always done in the Normal-R mode, which optimizes
for cell purity, as confirmed by re-analysis of the sorted
populations. Sorting was based according to level of
tHLA-Flu and CFSE staining of CD8-expressing T cells seg-
regating the tHLA-Flu+/CFSE- proliferating cells from the
tHLA-Flu-/CFSE+ non proliferating CTLs. Median purity
of Flu-specific and non-Flu-specific CTLs was above 95 %
in all experiments (Figure 1A). For the various sorting pro-
cedures the following monoclonal antibodies were used:
CD8-PE or CD8-FITC, CD3-PerCP (all from BD Bio-
sciences Pharmingen, San Diego, CA). As negative control
cells were stained with IgG FITC or PE conjugated, accord-
ing to the respective antibody's isotype. Cells were ana-
lyzed by FACS sort (BD Bioscience) gating them on living
CD3-expressing lymphocytes.
RNA handling for transcriptional profiling
Total RNA was isolated with RNeasy minikits (Qiagen,
Valencia, CA) and amplified into anti-sense RNA as previ-
ously described [15,16]. First strand cDNA synthesis was
accomplished in 1μl SUPERase·In (Ambion, Foster City,
CA) and ThermoScript RT (Gibco-Invitrogen, Carlsbad,
CA) in 2 μg bovine serum albumin. RNA quality was ver-
ified by Agilent technologies (Palo Alto). Anti-sense RNA
was labeled with Cy5-dUTP (Amersham, Piscataway, NJ)
and co-hybridized with reference pooled normal donor
peripheral blood mononuclear cells (PBMC) labeled with
Cy3-dUTP to custom made 17K-cDNA array platform
(UniGene cluster) printed at the Infectious Disease and
Immunogenetics Section, DTM, CC, NIH with a configu-
ration of 32 × 24 × 23 and contained 17,500 elements.
Clones used for printing included a combination of the
Research Genetics RG_HsKG_031901 8 k clone set and
9,000 clones selected from the RG_Hs_seq_ver_070700
40 k clone set. The 17,500 spots included 12,072 uniquely
named genes, 875 duplicated genes and about 4,000
expression sequence tags.
Arrays were scanned on a GenePix 4000 (Axon Instru-
ments) and analyzed using BRB-ArrayTools Version: 3.3,
Cluster and Tree View software.
Phenotyping and proliferation of Ag-activated CTLs
Cell culture
PBMCs from HLA-A*0201 healthy volunteers were
obtained from leukapheresis by Ficoll separation and kept
frozen in liquid nitrogen in aliquots of 108 cells/vial. At
day 0, PBMCs (1 vial/donor) were thawed and plated in
24 mw plates (2 × 106 cells/well). After resting overnight,
105 cells/donor were stained in order to determine the
percentage of CD8+ FLU+ T cells at day 1. All the remain-
ing cells were stimulated with Flu peptide (Flu M1:58-66,
1 μg/ml, Princeton Biomolecules, Langhorne, PA). The
day after cells in culture were harvested, counted and
plated in new 24 mw plates (2 × 106 cells/well) and
treated as follows: 1) untreated (Flu stimulation on day 1
only); 2) IL-2 (300 U/ml, Chiron, Emeryville CA); 3) IL-
2+GM-CSF (103 U/ml, PreProtech, Rocky Hill, NJ); 4)
GM-CSF; 5) IL-2+IFN-γ (500 U/ml, Actimmune, Brisbane,
CA); 6) IFN-γ. Cytokines were added every 2 days, replac-
ing each time half of the medium to avoid their accumu-
lation in the supernatant. At day 6 and 12, cells from 1
well/treatment were harvested, counted and stained for
FACS analysis.
FACS analysis
Harvested cells were washed with buffer and stained with
t-FLU-PE (FLU M1 iTAg MHC Tetramer, Beckman Coulter,
Miami, FL), mouse IgG1k anti CD8 PE-Cy5 (Becton Dick-
inson, Franklin Lakes, NJ), mouse IgG2a anti GM-CSF-R
(by Millipore, Billerica, MA, detected by using a secondary
antibody against mouse IgG2a Alexa 647 conjugated,
from Invitrogen, Carlsbad, CA), mouse IgG1k anti IFN-γ
Receptor β chain (Abcam, detected by using a secondary
antibody against mouse IgG1k Alexa 488 conjugated,
from Invitrogen). In order to avoid the reaction of the sec-
ondary antibody used for IFNγ detection with the Fc of the
IgG1k anti CD8, the staining for IFNγ receptor was per-
formed separately and anti CD8 was added after washing
as last step.




The raw data were filtered to exclude spots with minimum
intensity by arbitrarily setting a minimum intensity
requirement of 300 in both fluorescence channels. If the
fluorescence intensity of one channel was over and that of
the other below 300 the fluorescence of the low intensity
channel was arbitrarily set to 300. Spots with diameters <
25 μm and flagged spots were excluded from the analysis.
The filtered data were then normalized using the lowess
smother correction method. All statistical analyses were
performed using the log2-based ratios normalizing the
normal value in the array equal to zero.
Validation and reproducibility were measured using an
internal reference concordance system based on the
expectation that results obtained through the hybridiza-Journal of Translational Medicine 2008, 6:17 http://www.translational-medicine.com/content/6/1/17
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Gene expression profile: comparison between antigen specific and convivial non specific CD8+ T cells Figure 1
Gene expression profile: comparison between antigen specific and convivial non specific CD8+ T cells. A) repre-
sentative example of in vitro expansion of Flu M1:58-66-specific CD8 T cells in the presence of 300 IU/IL-2 and purity of the 
sorting procedure by high speed flow cytometry (FACSVantage SE); B) multiple dimensional scaling representing the four pop-
ulations of CD8 T cells based on the complete data set of 16,726 cDNA clones. CD8 expressing, CSFEhigh, Flu/tHLA negative T 
cells (non Flu specific) are referred to as IL-2 while CD8 expressing, CSFElow, Flu/tHLA positive T cells are referred to as IL-
2+Flu; C) Venn diagram displaying the extent of overlap between genes differentially expressed by Flu-specific and non Flu-spe-
cific CTLs from the same culture compared to quiescent CD8-expressing T cells; D) Multiple dimensional scaling plot repre-
senting Flu-specific and convivial CD8 T cells distribution using the complete data set of 16,726 cDNA clones.Journal of Translational Medicine 2008, 6:17 http://www.translational-medicine.com/content/6/1/17
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tion of the same test and reference material in different
experiments should perfectly collimate. The level of con-
cordance was measured by periodically re-hybridizing the
melanoma cell line A375-melanoma (American Type Cul-
ture Collection, Rockville MD) to the reference samples
consisting of pooled PBMCs as previously described [17].
This analysis demonstrated a higher than 95% concord-
ance level. Non-concordant genes were excluded from
subsequent analysis.
Supervised class comparison utilized the BRB ArrayTool
[18] developed at NCI, Biometric Research Branch, Divi-
sion of Cancer Treatment and Diagnosis. Paired samples
were compared with a two-tailed paired Student t test.
Unpaired samples were tested with a two-tailed un-paired
Student t test assuming unequal variance or with an F test
as appropriate. All analyses were tested for a univariate
significance threshold set at a p2-value < 0.005. Gene clus-
ters identified by the univariate t test were challenged with
two alternative additional tests, a univariate permutation
test (PT) and a global multivariate PT. The multivariate PT
was calibrated to restrict the false discovery rate to 10%.
Genes identified by univariate t  test as differentially
expressed (p2-value < 0.005) and a PT significance < 0.05
were considered truly differentially expressed. Gene func-
tion was assigned based on Database for Annotation, Vis-
ualization and Integrated Discovery (DAVID) and
Genontology. Multiple dimensional scaling was per-
formed using the BRB Array tool.
Functional studies
Fold increase in CD8+ FLU+ T cells was based on the cal-
culation of the absolute number of CD8 expressing T cells
at day 1, day 6 and day 12. Their fold increase (FI) was cal-
culated by dividing their number at day 6 and 12 over
their starting number at day 1. The same assessment was
done for flu-positive and flu-negative CTLs. Average and
standard error from the mean (SEM) are presented as
appropriate. A paired Student t test was applied to calcu-
late level of significance.
Results and discussion
Global Differences between Ag-stimulated, IL-2-activated 
and quiescent CD8 expressing T cells
There were extensive differences between quiescent CD8
expressing T cells analyzed ex vivo and their counterparts
maintained in in vitro culture in the presence of 300 IU IL-
2 and Ag stimulation. An univariate F-test with random
variance model identified 4,702 clones out of 16,726
present in the array to be differentially expressed at a p-
value < 0.001. The probability of randomly obtaining this
number of genes at the selected level of significance (p <
0.005) if there were no real differences among groups was
calculated as 0 by multivariate permutation test (Table 1).
To assess for possible effects due to the in vitro culture con-
ditions, we maintained PBMCs in culture for 24 hours in
the absence of IL-2 and sorted CD8 expressing T cells
before transcriptional profiling. This control demon-
strated high similarity of in vitro maintained CD8 T cells
with the profile of ex vivo analyzed CD8 T cells. Thus, the
functional genomics changes observed in in vitro stimu-
lated CD8 T cells are specific to stimulation and not sim-
ply due to in vitro culture artifacts. Multiple dimensional
scaling based on the global 16,726 cDNA clone data set
clearly separated the ex vivo and in vitro quiescent from the
in vitro activated populations (Figure 1B).
Analysis of individual experimental conditions against
each other demonstrated that the biggest differences in
transcriptional patterns were present between the Flu-spe-
cific CTLs stimulated in vitro and the quiescent ex vivo CD8
T cells (three way t test) with the least differences noted
between the Flu-specific CTLs and the convivial non-Flu-
specific CTLs from the same culture.
Transcriptional patterns shared by Ag-specific and 
convivial CTLs compared to quiescent ex vivo analyzed 
CD8-expressing T cells
The transcriptional pattern of in vitro stimulated CTLs
whether exposed to Ag (Flu-specific CD8 T cells) or only
to IL-2 was similar relative to that of ex vivo isolated or in
Table 1: Difference in the transcriptional pattern of quiescent compared to stimulated CD8 T cells
Class Comparison # of genes differentially expressed at Student 
t test or F test p2-value < 0.001
Permutation Test (p-value) Multivariate
Ex vivovs CD8 in culture vs IL-2 vs IL-2+Flu 6,692 (F test, n = 24) 0
Ex vivovs combined IL-2 and IL-2+Flu 5,527 (t test, n = 18) 0
Ex vivovs IL-2 vs IL-2+Flu 4, 702 (F test, n = 18) 0
Ex vivovs IL-2 4,893 (t test, n = 12) 0
Ex vivovs IL-2+Flu 5, 859 (t test, n = 12) 0
IL-2 vs IL-2+Flu 1,727 (t test), n = 12 0
Ex vivo refers to the transcriptional analysis of freshly isolated and processed CD8 positive T cells; CD8 T cells were also sorted by high speed 
FACS sorter from PBMC from HLA-A*0201 expressing normal donors that had been cultured for 7 days in the presence of 300 IU IL-2 following 
stimulation with the Flu M1:58-66 peptide according to their level of CFSE and Flu/tHLA staining. CD8 expressing, CSFEhigh, Flu/tHLA negative T 
cells (non Flu specific) are referred to as IL-2 while CD8 expressing, CSFElow, Flu/tHLA positive T cells are referred to as IL-2+FluJournal of Translational Medicine 2008, 6:17 http://www.translational-medicine.com/content/6/1/17
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vitro  maintained CD8 T cells. In particular, multiple
dimensional scaling based on the complete 16,726 gene
data set clearly separated the unstimulated from the stim-
ulated populations. Of 5,859 genes differentially
expressed between Flu-specific CTLs and ex vivo CD8 T
cells, 3,639 were concordantly expressed by convivial
CTLs (Figure 1C). Thus, CTLs maintained in the same cul-
ture demonstrate similar transcriptional patterns inde-
pendent of their exposure to Ag-specific stimulation.
Among the genes similarly up-regulated in both sub-
groups of stimulated T cells were perforin, granzyme A,
TNF-α and the IL-2 receptor α chain. Overall, the tran-
scriptional profile of the genes concordantly expressed by
in vitro stimulated CTLs was similar to that of our previous
reported analysis [13].
Transcriptional patterns specific to Ag-specific activation
The aim of this study was to identify those signatures that
are determined by the long term effects of Ag stimulation
independent of other co-existing factors that may influ-
ence the activation and function of CD8+ T cells. For this
reason, we focused our analysis on genes that were differ-
entially expressed between CFSEhigh, Flu/tHLA positive
CD8 T cells and CSFElow, Flu/tHLA negative CD8 T cells.
An unpaired t test identified 1,727 genes to be differen-
tially expressed between the two populations at a p2-vlue
< 0.001 (Table 1). It should be clarified that several of
these genes were concordantly differentially expressed in
both subpopulations compared with quiescent ex vivo iso-
lated CD8-expressing T cells. However, the degree in
which the expression was altered in the two subsets was
sufficiently different to result in significant differences
between the two populations. The differences identified
were significant according to the multivariate permuta-
tion test (p-value = 0). Multiple dimensional scaling anal-
ysis based on the complete date set confirmed the
separation of the two populations (Figure 1D).
Among the genes differentially expressed by the two pop-
ulations 644 were up-regulated in Ag-specific CTLs com-
pared to convivial CTLs. The rest (1,083) were down-
regulated. The annotations related to biological functions
derived through gene ontology suggested that the genes
that were predominantly up-regulated in Ag-specific CTLs
belong to several categories. Although some categories
appeared particularly enriched, they contained a relatively
small number of genes, while the categories with the larg-
est absolute number of genes included: cell cycle and cell
division (111 genes), response to endogenous stimulus
(45 genes) and cytokine production (17 genes). Gene
Ontology analysis suggested, therefore, that even seven
days after the original stimulus the predominant differ-
ences between Ag-exposed Flu-specific CTLs and their cul-
ture companions were related to a broader activation of
pro-proliferative stimuli, signaling and cytokine produc-
tion in the former.
Gene Ontology was also applied to identify genes associ-
ated with immunological functions; this analysis identi-
fied 58 (expected number 52.8; observed over expected
ratio = 1.10) up-regulated in the Flu-specific CTLs and 212
out of 988 (expected number 80.3; observed over
expected ratio = 2.64) down-regulated relative to the con-
vivial CTLs (Fisher test p2-value < 0.001).
The immunologically-related genes most expressed by Ag-
activated or convivial CTLs are shown in Table 2. The tran-
script most abundant in Ag-specific CTLs was IFN-γ (Fig-
ure 2). Conversely, IFN-γ receptor 2 (β-chain) ranked
highest among the immune genes up-regulated bye con-
vivial CTLs, which paralleled the over-expression of inter-
feron-stimulated genes (ISGs) selectively in these cells
while ISGs where completely shut off in Ag-activated
CTLs. The lack of expression of ISGs by Ag-activated CTLs
was associated with lack of expression of the IFN-γ recep-
tor α and β and the IFN-γ receptor accessory factor AF-1.
This observation suggested that Ag-activated, terminally
differentiated CTLs shelter themselves from the poten-
tially harmful autocrine effects of IFN-γ. This observations
supports the lack of responsiveness of Ag-specific T cells to
IFN-γ during the expansion phase which is slowly
regained during the contraction phase previously reported
in an experimental animal model [19]. On the other
hand, Ag-stimulated CTLs expressed higher levels of CSF2
receptor β chain, (GM-CSF/IIL-5/IL-3 receptor common
β-chain, CSFR2B, CD131), chemokine (C-X-C motif)
receptor 6 (CXCR6), C-C chemokine receptor 1 (CCR1)
and IL-2R α- and β-chains. In addition, Ag-stimulated
CTLs strongly down-regulated the chemokine (C-C motif)
receptor 7 in accordance with their effector T cell differen-
tiation. Interestingly, the over-expression of CD131 was
associated with very high expression of its ligand colony
stimulating factor 2 (CSF2, GM-CSF) suggesting that this
autocrine loop may play an important role in promoting
their survival. Moreover, several cytokines were produced
including chemokine (C-C motif) ligand 3 (CCL3, MIP-
1α), ligand 4 (CCL4, MIP-1β) and ligand 18 (CCL18,
PARC).
Ag-activated CTLs also expressed higher levels of
granzyme B and to a lesser degree granzyme A while their
convivial counterparts expressed high levels of granzyme
K. As previously observed, Perforin, was strongly and
equally un-regulated in both populations compared to
quiescent CD-expressing T cells studied ex vivo or in vitro
[4].
Finally, Ag-activated CTLs expressed higher levels of the
co-stimulatory molecules CD80 and CD86.Journal of Translational Medicine 2008, 6:17 http://www.translational-medicine.com/content/6/1/17
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GMCSF effects on Ag-specific CTLs
The high levels of IFN-γ and GMSCF transcript (but not
protein) expression together it the up-regulation of
CMCSF receptor β chain (CD131) and the down regula-
tion of the IFN-γ receptors I and II by Ag-activated CTLs
suggested the intriguing possibility of a bipolar relation-
ship of Ag-activated CTLs with the potential autocrine
effects of the two cytokines. It appears that Ag-activated
CTLs shield themselves from the potential harmful affects
of IFN-γ [20] while accepting the potentially proliferative
support of GM-CSF; a growth factor without known pro-
apoptotic functions [21]. This bipolar behavior may
explain the selective survival and expansion of Ag-stimu-
lated CTLs in vitro (an potentially in vivo).
To test the potential of such hypothesis, we analyzed
CD131 expression by Flu-specific CTLs. As shown in Fig-
ure 3, at day 6 and 12 Flu-specific CTLs consistently
express CD131 which is totally absent in the convivial
CTLs. IVS of HLA-A*0201-expressing PBMCs with 1 μM
Flu M1:58-66 peptide in the presence of IL-2, GMCSF,
IFN-γ or a combination of the them with IL-2 demon-
strated that while GMCSF (1,000 U/ml) selectively
enhances the expansion of Flu-specific CTLs after 12 days
in culture when combined to IL-2 (300 IU/ML) adminis-
tration while IFN-γ (500 U/ml) has no effect consistent
with their lack of expression of the IFN receptors (Figure
3C). Not the combination IL-2+GMCSF nor other
Gene expression profile: comparison between antigen specific and convivial non specific CD8+ T cells Figure 2
Gene expression profile: comparison between antigen specific and convivial non specific CD8+ T cells. A) Selec-
tion of genes among 1,727 genes differentially expressed between Flu-specific (green bar) and convivial (red bar) CD8 T cells at 
a t test p2-value < 0.001 whose annotation includes the word "interferon". The table displays the gene symbol, its name and the 
level of differential expression (Δ) as the CY5/CY3 ratio of fly-specific versus convivial in green and vice versa in red.Journal of Translational Medicine 2008, 6:17 http://www.translational-medicine.com/content/6/1/17
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cytokine combination exerted any effect on the prolifera-
tion of convivial CTLs (data not shown).
In conclusion, this preliminary study suggests that, at least
during IVS, preferential survival/expansion of Ag-acti-
vated CTL may be partially mediated through a bipolar
regulation of their sensitivity to the autocrine secretion of
cytokines; IFN-γ and GMCSF appear to play a dominant
role at this junction as other two cytokines known to be
produced by activated CTLs (TNF-α and IL-2) where sim-
ilarly highly expressed at the transcriptional level by both
Ag-activated and convivial CTLs. The confirmation of the
selective expression of CD131 on the surface of Ag-acti-
vated CTLs and its likely functional association with the
selective response of Ag-activated CTLs to exogenous GM-
CSF suggests a previously unreported positive feed back
autocrine loop that may stimulate CTL growth in response
to further Ag stimulation [21]. In addition, the positive
role that GMCSF may play in the proliferation of CD131-
expressing Ag-activated CTLs, may explain the beneficial
effects of this cytokine used as vaccine adjuvant, which
has been so far attributed exclusively to its role in activat-
ing and maturing antigen presenting cells [22]. Finally,
the selective expression of CD131 by Ag-activated CTLs
may qualify this surface marker as a non Ag-specific
biomarker of Ag-specific CTL activation. Although exten-
sive in vivo and in vitro validation is required to support
such hypotheses, we believe that the novelty and the
potential biological implications of these findings war-
rant a preliminary disclosure.
Table 2: 
Immune Genes Up-regulated in Flu-specific CD8 T cells Immune GenesUp-regulated in convivial CD8 T cells
Symbol Δ Symbol Δ
IFNG Interferon gamma 8.64 IFNGR2 interferon-γ receptor 2 7.73
CSF2 Colony stimulating factor 2 7.55 GZMK granzyme K 7.12
CCL3 Chemokine (C-C motif) ligand 3 7.13 XCL1 Chemokine (C motif) ligand 1 6.39
CD38 CD38 6.99 SOCS3 STAT induced STAT inhibitor-3 = CIS3 5.02
CD80 CD80 = B7-1 6.90 CX3CR1 Chemokine (C-X3-C motif) receptor 1 4.91
CSF2RB Colony stimulating factor 2 receptor, beta 5.58 CCR7 Chemokine (C-C motif) receptor 7 4.58
APOA2 Apolipoprotein A-II 5.13 TIMP2 TIMP metallopeptidase inhibitor 2 4.53
GZMB Granzyme B 4.72 IL24 interleukin 24 4.47
CSF2RB GM-CSF/IL-5/IL-3 receptor common beta chain 3.64 PF4 Platelet factor 4 (chemokine) ligand 4 4.29
GNLY Granulysin 3.62 LY86 Lymphocyte antigen 86 4.26
CCL4 MIP-1 beta 3.54 ITGA6 CD49F = Integrin alpha 6 3.75
CD86 CD86 = B7.2 3.54 PECAM1 platelet/endothelial cell adhesion molecule (CD31) 3.37
CD226 adhesion molecule DNAM-1 3.51 LY9 lymphocyte antigen 9 2.97
CXCR6 Chemokine (C-X-C motif) receptor 6 3.32 JAK1 Janus kinase 1 2.68
ITGA2 Integrin, alpha 2 (CD49B) 3.30 TNFSF13 Tumor necrosis factor superfamily13 2.68
DUSP16 Dual specificity phosphatase 16 2.91 IL8 Interleukin 8 2.55
IL1RAP Interleukin 1 receptor accessory protein 2.37 TIMP1 tissue inhibitor of metalloproteinase 1 2.47
CCR1 C-C chemokine receptor 1 2.30 CISH Cytokine inducible SH2-containing protein 2.46
DUSP5 dual specificity phosphatase 5 2.27 CD163 CD163 2.39
ITGB7 CD103 beta = Integrin beta 7 2.22 CTSS Cathepsin S 2.17
ICOS inducible T-cell co-stimulator 2.22 GABBR1 GABA-BR1a (hGB1a) receptor 2.16
DUSP10 Dual specificity phosphatase 10 1.88 SELL CD62L = L-selectin 2.16
GZMA Granzyme A 1.43 CXCL1 GRO1 = GRO α 2.15
CTSD Cathepsin D 1.43 CSF3R G-CSF receptor 2.14
ENTPD1 CD39 1.31 GRN Granulin 2.06
CCL18 PARC 1.10 CD33 CD33 molecule 2.04
CD58 LFA-3 1.10 IL11RA IL-11 receptor α chain 1.90
IL2RB IL-2 receptor beta chain 1.07 CXCR4 chemokine (C-X-C motif), receptor 4 (fusin) 1.85
CCL2 MCP-1 1.06 IL7R IL-7 receptor α chain 1.58
CTSC Cathepsin C 0.98 VEGFB Vascular endothelial growth factor B 1.55
IL2RA interleukin 2 receptor, alpha 0.92 IL4R IL-4 receptor α chain 1.45
STAT1 STAT1 1.39
IFNGR1 interferon-gamma receptor α chain 1.33Journal of Translational Medicine 2008, 6:17 http://www.translational-medicine.com/content/6/1/17
Page 9 of 10
(page number not for citation purposes)
References
1. Kaech SM, Hemby S, Kersh E, Ahmed R: Molecular and functional
profiling of memory CD8 T cell differentiation.  Cell 2002,
111:837-851.
2. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia
R, von Andrian UH, Ahmed R: Lineage relationship and protec-
tive immunity of memory CD8 T cell subsets.  Nature Immunol
2003, 4(3):225-234.
3. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Ham-
merbeck CD, Popescu F, Xiao Z: Signals required for program-
ming effector and memory development by CD8+ T cells.
Immunol Rev 2006, 211:81-92.
4. Monsurro' V, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K,
Nagorsen D, Connors M, Jacobson S, Marincola FM: Quiescent
phenotype of tumor-specific CD8+ T cells following immuni-
zation.  Blood 2004, 104:1970-1978.
CD131 expression following IVS with Flu M1:58-66 peptide Figure 3
CD131 expression following IVS with Flu M1:58-66 peptide. Expression of CD131 (GMCSF receptor β chain) in Flu 
M1:58-66-activated (tHLA/Flu +) and convivial (tHLA/Flu-) CTLs (corresponding to R4 and R7 in Figure 1) after 6 (A) and 12 
(B) days of IVS of HLA-A*0201 expressing PBMCs in the presence of 300 IU/ml of IL-2; C – Fold increase (FI) of HLA-A*0201 
PBMCs exposed to IVS with Flu M1:58-66 peptide (Flu) plus exogenous administration every other day of IL-2 (300 IU/ml), 
GMCSF (1,000 U/ml), IFN-γ (500 IU/ml) or a combination of them for 6 (white bars) or 12 (black bars) days. Data are pre-
sented as average ± standard error from the mean of 5 experiments performed in PBMCs from 5 different donors; * and ** = 
paired Student t test p-value ≤ 0.05 and ≤ 0.01 respectively between comparing FI in individuals experimental groups with the 
FI in respective PBMC populations stimulated only with Flu; The difference in significance between Flu+IL-2+GMCSF FI at day 
12 and that of Flu+IL-2 and Flu+IL-2+IFN-γ are outlined specifically in the graph.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Translational Medicine 2008, 6:17 http://www.translational-medicine.com/content/6/1/17
Page 10 of 10
(page number not for citation purposes)
5. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA: Shared
human melanoma antigens. Recognition by tumor- infiltrat-
ing lymphocytes in HLA-A2.1-transfected melanomas.  J
Immunol 1992, 148:638-643.
6. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles.S., Connors M,
Steinberg SM, Rosenberg SA, Marincola FM: Increased vaccine-
specific T cell frequency after peptide-based vaccination cor-
relates with increased susceptibility to in vitro stimulation
but does not lead to tumor regression.  J Immunol 1999,
163:6292-6300.
7. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith SM, Ahmed R:
Therapeutic use of IL-2 to enhance antiviral T-cell responses
in vivo.  Nat Med 2003, 9:540-547.
8. Panelli MC, Wang E, Phan G, Puhlman M, Miller L, Ohnmacht GA,
Klein H, Marincola FM: Gene-expression  profiling of the
response of peripheral blood mononuclear cells and
melanoma metastases to systemic IL-2 administration.
Genome Biol 2002, 3:RESEARCH0035.
9. Panelli MC, Stashower M, Slade HB, Smith K, Norwood C, Abati A,
Fetsch PA, Filie A, Walters SA, Astry C, Arico E, Zhao Y, Selleri S,
Wang E, Marincola FM: Sequential gene profiling of basal cell
carcinomas treated with Imiquimod in a placebo-controlled
study defines the requirements for tissue rejection.  Genome
Biol 2006, 8:R8.
10. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M,
Salvatierra O Jr.: Molecular heterogeneity in acute renal allo-
graft rejection identified by DNA microarray profiling.  N Engl
J Med 2003, 349:125-138.
11. Smith MW, Yue ZN, Korth MJ, Do HA, Boix L, Fausto N, Bruix J, Car-
ithers RL Jr., Katze MG: Hepatitis C virus and liver disease: glo-
bal transcriptional profiling and identification of potential
markers.  Hepatology 2003, 38:1458-1467.
12. Mantovani A, Romero P, Palucka AK, Marincola FM: Tumor immu-
nity: effector response to tumor and the influence of the
microenvironment.  Lancet 2008, 371:771-783.
13. Jin P, Wang E, Provenzano M, Deola S, Selleri S, Jiaqiang R, Voiculescu
S, Stroncek DF, Panelli MC, Marincola FM: Molecular signatures
induced by interleukin-2 on peripheral blood mononuclear
cells and T cell subsets.  J Transl Med 2006, 4:26.
14. Adams S, Robbins FM, Chen D, Wagage D, Holbeck SL, Morse HC III,
Stroncek D, Marincola FM: HLA class I and II genotype of the
NCI-60 cell lines.  J Transl Med 2005, 3:11.
15. Wang E, Miller L, Ohnmacht GA, Liu E, Marincola FM: High fidelity
mRNA amplification for gene profiling using cDNA microar-
rays.  Nature Biotech 2000, 18(4):457-459.
16. Wang E: RNA amplification for successful gene profiling anal-
ysis.  J Transl Med 2005, 3:28.
17. Jin P, Zhao Y, Ngalame Y, Panelli MC, Nagorsen D, Monsurro' V,
Smith K, Hu N, Su H, Taylor PR, Marincola FM, Wang E: Selection
and validation of endogenous reference genes using a high
throughput approach.  BMC Genomics 2004, 5:55.
18. NCI NIH: BRB ArrayTool Site.  http://www linus nci nih gov/BRB-
ArrayTools html 2006.
19. Haring JS, Corbin GA, Harty JT: Dynamic regulation of IFN-
gamma signaling in antigen-specific CD8+ T cells responding
to infection.  J Immunol 2005, 174:6791-6802.
20. Bernabei P, Allione A, Rigamonti L, Bosticardo M, Losana G, Borghi I,
Forni G, Novelli F: Regulation of interferon-gamma receptor
(INF-gammaR) chains: a peculiar way to rule the life and
death of human lymphocytes.  Eur Cytokine Netw 2001, 12:6-14.
21. Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G, Zhang Y, Zhang L,
Yuan ZR, Tan HS, Das G, Devadas S: Granulocyte-macrophage
colony-stimulating factor (GM-CSF) and T-cell responses:
what we do and don't know.  Cell Res 2006, 16:126-133.
22. Eager R, Nemunaitis J: GM-CSF gene-transduced tumor vac-
cines.  Mol Ther 2005, 12:18-27.